A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study M.-C. Tsai,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

L.H. Su, T.L. Wu, C.H. Chiu Clinical Microbiology and Infection

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

R. Cavallo Clinical Microbiology and Infection

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience M.-C.

L. Boyanova Clinical Microbiology and Infection

High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China X.-S. Chen, Y.-P. Yin, W.-H. Wei, H.-C. Wang,

Gut bacterial microbiota and obesity

L.H. Su, T.L. Wu, C.H. Chiu Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

Molecular characterization of methicillin-resistant Staphylococcus aureus isolated over a 2-year period in a Qatari hospital from multinational patients

Herpes zoster in non-hospitalized children

The relationship between tumour necrosis factor-α gene polymorphism and susceptibility and clearance of the persistent hepatitis B virus infection in.

Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome.

Mycobacterial peritonitis: difference between non-tuberculous mycobacteria and Mycobacterium tuberculosis C.-C. Shu, J.-T. Wang, J.-Y. Wang, C.-J. Yu,

J. Ambrosioni, A. Mamin, A. Hadengue, M. Bernimoulin, K. Samii, C

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Candida glabrata fungaemia in intensive care units

J.-P. Van geertruyden Clinical Microbiology and Infection

Hepatitis B and C virus-related carcinogenesis

Infectious causes of cancer: an evolving educational saga

Virological tools to diagnose and monitor hepatitis C virus infection

Recurrent late-onset sepsis in the neonatal intensive care unit: incidence, clinical characteristics and risk factors M.-H. Tsai, S.-M. Chu, C.-W. Lee,

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

R. Cantón Clinical Microbiology and Infection

Multicentre surveillance of prevalence of the 23S rRNA A2058G and A2059G point mutations and molecular subtypes of Treponema pallidum in Taiwan, 2009–2013

Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection Y.W.

Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure Y.-C. Wang, Y.-T.

E. Braun, K. Hussein, Y. Geffen, G. Rabino, Y. Bar-Lavie, M. Paul

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic A.S.

Volume 133, Issue 5, Pages (November 2007)

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Vector control: a cornerstone in the malaria elimination campaign

A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China Y. Zhang,

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

J. Du, X. Wang, Y. Hu, Z. Li, Y. Li, S. Sun, F. Yang, Q. Jin

Estimation of delay in detecting hepatitis C virus antibodies in pools compared to individual testing on seroconversion panels B. Sarov, L. Novack, N.

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Z. Wang, Z. Cui, Y. Li, T. Hou, X. Liu, Y. Xi, Y. Liu, H. Li, Q. He

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Early invasive fungal infections and colonization in patients with cirrhosis admitted to the intensive care unit E. Theocharidou, B. Agarwal, G. Jeffrey,

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Hepatitis B and C virus-related carcinogenesis

L. -N. Lee, C. -H. Chou, J. -Y. Wang, H. -L. Hsu, T. -H. Tsai, I. -S

J. Garau Clinical Microbiology and Infection

T.M. File Clinical Microbiology and Infection

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

The role of antimalarial treatment in the elimination of malaria

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Current experience in treating invasive zygomycosis with posaconazole

Reducing antibiotic use in influenza: challenges and rewards

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic.

Presence of sandflies infected with Leishmania infantum and Massilia virus in the Marseille urban area† B. Faucher, R. Piarroux, C. Mary Clinical Microbiology.

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

The future of diagnostic bacteriology

Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients D. He, S. Guo, P. Zhu, S. Tao, M. Li,

Presentation transcript:

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study M.-C. Tsai, C.-H. Chen, C.-H. Hung, C.-M. Lee, K.-W. Chiu, J.-H. Wang, S.-N. Lu, P.-L. Tseng, K.-C. Chang, Y.-H. Yen, T.-H. Hu Clinical Microbiology and Infection Volume 20, Issue 2, Pages O90-O100 (February 2014) DOI: 10.1111/1469-0691.12220 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Comparison of efficacy results between telbivudine and entecavir at year 2 (the intension-to-treat population). Clinical Microbiology and Infection 2014 20, O90-O100DOI: (10.1111/1469-0691.12220) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 Cumulative rate of hepatitis B virus e antigen (HBeAg) seroconversion between telbivudine and entecavir groups. Roadmap and super-responders concepts were proposed by Keeffe et al. [7] and Zeuzem et al. [8]. Clinical Microbiology and Infection 2014 20, O90-O100DOI: (10.1111/1469-0691.12220) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 3 Cumulative rate of resistance between telbivudine and entecavir groups. Roadmap and super-responders were proposed by Keeffe et al. [7] and Zeuzem et al. [8]. Clinical Microbiology and Infection 2014 20, O90-O100DOI: (10.1111/1469-0691.12220) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 4 Cumulative rate of hepatocellular carcinoma (HCC) development between (a) telbivudine and entecavir. (b) liver cirrhosis and non-liver cirrhosis. (c) resistance and non-resistance groups. Clinical Microbiology and Infection 2014 20, O90-O100DOI: (10.1111/1469-0691.12220) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 5 The mean of creatinine (a) and estimated glomerular filtration rate (eGFR). (b) between telbivudine and entecavir groups at baseline, year 1 and year 2. Clinical Microbiology and Infection 2014 20, O90-O100DOI: (10.1111/1469-0691.12220) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 6 Estimated glomerular filtration rate (eGFR) mean change from baseline to year 1 between telbivudine and entecavir groups Clinical Microbiology and Infection 2014 20, O90-O100DOI: (10.1111/1469-0691.12220) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions